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ABSTRACT
Background: Previous cross-sectional studies have
shown that job change due to breathing problems at the
workplace (respiratory work disability) is common among
adults of working age. That research indicated that
occupational exposure to gases, dust and fumes was
associated with job change due to breathing problems,
although causal inferences have been tempered by the
cross-sectional nature of previously available data. There
is a need for general population-based prospective studies
to assess the incidence of respiratory work disability and
to delineate better the roles of potential predictors of
respiratory work disability.
Methods: A prospective general population cohort study
was performed in 25 centres in 11 European countries
and one centre in the USA. A longitudinal analysis was
undertaken of the European Community Respiratory
Health Survey including all participants employed at any
point since the baseline survey, 6659 subjects randomly
sampled and 779 subjects comprising all subjects
reporting physician-diagnosed asthma. The main outcome
measure was new-onset respiratory work disability,
defined as a reported job change during follow-up
attributed to breathing problems. Exposure to dusts
(biological or mineral), gases or fumes during follow-up
was recorded using a job-exposure matrix. Cox propor-
tional hazard regression modelling was used to analyse
such exposure as a predictor of time until job change due
to breathing problems.
Results: The incidence rate of respiratory work disability
was 1.2/1000 person-years of observation in the random
sample (95% CI 1.0 to 1.5) and 5.7/1000 person-years in
the asthma cohort (95% CI 4.1 to 7.8). In the random
population sample, as well as in the asthma cohort, high
occupational exposure to biological dust, mineral dust or
gases or fumes predicted increased risk of respiratory work
disability. In the random sample, sex was not associated
with increased risk of work disability while, in the asthma
cohort, female sex was associated with an increased
disability risk (hazard ratio 2.8, 95% CI 1.3 to 5.9).
Conclusions: Respiratory work disability is common
overall. It is associated with workplace exposures that
could be controlled through preventive measures.
In recent years, clinicians, researchers and insurers
have paid increasing attention to questions of work
disability, including ways to improve disability
evaluations and approaches to better aid patients
in their return to work. In this context, critical
knowledge gaps must be addressed. For this effort,
it is important to recognise the difference between
having a health condition and experiencing dis-
ability, including work disability, as a disease may
be present without concurrent disability.1 The
aetiology of work disability is likely to be multi-
factorial and to reflect the interaction between the
person with a health condition causing impairment
and the environment in which that person is
found. This interaction may induce or aggravate
symptoms, further limiting functional ability and
thus increasing the likelihood of disability. This
pathway is particularly germane to respiratory
disease. Severity of disease is a clear predictor for
work disability among adults with asthma,2 3 and
occupational exposures to irritants and dusts have
been shown to promote respiratory disability.3–7
Respiratory work disability may be defined in a
number of ways. Its most severe manifestation is
complete cessation of employment due to respira-
tory difficulties. In addition, there are a number of
other important measures of occupational disabil-
ity, including lost work days, change in employ-
ment, limitation in job duties or reduction in work
hours due to respiratory symptoms or disease.8
Current knowledge in this field is based on data
from cross-sectional studies or from hospital-
derived or physician-based panels of persons with
asthma or other respiratory diseases. There is a
clear need for general population-based prospective
studies to assess the incidence of respiratory work
disability and to delineate better the roles of
potential predictors of respiratory work disability.
The present study is based on follow-up of an
international general population study (European
Community Respiratory Health Survey, ECRHS)
comprising both a general population sample and a
group of subjects with asthma at baseline.9 The
aim is to measure the frequency of respiratory
work disability in the general population and to
estimate the impact of workplace exposures as risk
factors for new-onset respiratory-related work
disability.
METHODS
Baseline and follow-up ECRHS
The methodology of the ECRHS II has been
described elsewhere.9 10 In the baseline study
(ECRHS I, 1991–3), participating study centres
used a short respiratory questionnaire to study a
random sample of at least 3000 subjects per centre
aged 20–44 years. Among the responders in the
baseline study, both a random subsample of 20% of
all subjects and a respiratory symptom-enriched
group were invited to participate in a clinical
investigation. At follow-up in 1998–2002 (ECRHS
II), subjects from both the random and the
symptom-based samples who participated at
baseline were invited to complete a follow-up
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respiratory questionnaire and to participate in the second
clinical investigation. Follow-up participation was achieved for
64% of the eligible baseline subjects.
Definition of study group
In the present study, two partially overlapping groups from
ECRHS II were analysed—the random sample and a sample of
subjects who reported physician-diagnosed asthma at the time
of the baseline ECRHS I study. This ‘‘asthma cohort’’ included
both subjects from the random sample and subjects from the
symptom-enriched sample.
For the current analysis, subjects were required to meet the
following criteria: a complete occupational history recorded at
follow-up as well as no other missing data for key study
predictors or outcomes; employment at any point since the
baseline survey; and absence of reported respiratory work
disability at baseline (job change attributed to breathing
affected by work).
The final study population for this analysis comprised 6659
subjects from the random sample and 779 subjects from the
asthma cohort, of which 394 (51%) originated from the random
sample and 385 (49%) from the symptom-based sample. The
subjects were from 25 centres in 11 European countries and one
centre in the USA (fig 1).
Respiratory work disability
Respiratory work disability was defined as a positive response at
the follow-up to the questionnaire item: ‘‘Have you had to leave
any job (during follow-up) because it affected your breath-
ing?’’5–7 Affirmative questionnaire responses to this item were
followed up with identification of the specific employment
involved.
Predictor variables
Occupations during the period of follow-up, including start-year
and stop-year, were classified according to the International
Standard Classification of Occupations.11 A job-exposure matrix
(JEM) used these codes to classify each job in an individual’s
employment history. The codes were linked to a JEM (ALOHA-
JEM) to further classify each job as being of likelihood of
exposure rated none, low (intermediate) or high for each of
three categories of inhalants, biological dust, mineral dust and
gases or fumes.12 13 This allowed collapse of exposure likelihood
to address any of the three exposures. Thus, a low likelihood for
biological dust, none for mineral dust and a high likelihood for
exposure to gas or fumes would be assigned a high likelihood of
any exposure. For subjects experiencing the event (respiratory
work disability), only jobs until the event were taken into
account to assess exposure.
A continuous 5-point scale symptom score was computed
based on the following five questions concerning asthma-like
characteristics during the last 12 months: wheeze with breath-
lessness; woken with tightness in chest; attack of shortness of
breath at rest; attack of shortness of breath after exercise; and
woken by attack of shortness of breath.14 Each is scored 1 point,
with the resulting score potentially ranging from 0 to 5. We
used this score as a proxy of active respiratory disease at baseline
in the asthma cohort.
Smoking was classified based on information at baseline. Atopy
was defined as a specific IgE level .0.35 kU/l to at least one of
house dust mite, cat, timothy grass or Cladiosporium herbarum.15
Forced expiratory volume in 1 s (FEV1) was obtained at baseline
for 6084 (91%) of the random sample and 709 (91%) of the asthma
cohort by means of spirometry using standardised methods.12
Data analysis
The analyses were carried out using SAS Version 8.3 and
STATA 10.0. Hazard ratios (HR) and 95% confidence intervals
(95% CI) for respiratory work disability were modelled using
Cox proportional hazards regression analyses. The outcome
event was defined as respiratory work disability and time until
event was determined by reported date of leaving the job in
which the disability was reported. The exposure was analysed
as a joint JEM exposure (biological dust, mineral dust, gases and
fumes) or as separate exposure likelihoods for each subcategory
of exposure.
In the multivariate models, potential confounders were
selected a priori. These included geographical areas (English
speaking (referent), northern, central and southern European
countries), sex, age at follow-up, symptom score at baseline
(treated as a continuous variable, smoking status at baseline
(never, former and current) and exposure to passive smoking at
work (at baseline), as well as one model using pack-years. When
analysing the impact of each specific occupational exposure, the
models also included the other two exposures. All models were
run separately for the random sample and the asthma cohort, and
stratified by sex and atopy. The main unstratified models were
also run again, limited to non-asthmatic subjects in the random
sample. Symptom scores were reanalysed, creating indicator
variables for different numbers of cumulative symptoms with the
referent category being no symptoms. We also re-estimated the
basic model substituting FEV1% for the symptom score.
RESULTS
The characteristics of the random population sample and
the asthma cohort are shown in table 1. The mean length of
Figure 1 Flow chart of the selection of included subjects.
ECRHS, European Community Respiratory Health Survey.
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follow-up was 8.9 years in the random sample and 8.7 years in
the asthma cohort, accumulating 59 265 person-years and
6777 person-years, respectively. The crude incidence rate of
respiratory work disability was 1.2/1000 person-years of obser-
vation (95% CI 1.0 to 1.5) in the random sample and 5.7/
1000 person-years of observation (95% CI 4.1 to 7.8) in the
asthma cohort. The prevalence of occupational exposures based
on JEM assignments in the two groups are shown in table 2.
Altogether, a high likelihood of any exposure was present in 976
(15%) of the random sample and 101 (13%) of the asthma
cohort which, as noted, overlaps the former group.
Random sample
Among subjects in the random population sample, a low
likelihood of any occupational exposure to biological dust,
mineral dust or gases or fumes conferred an increased risk of
respiratory work disability (HR 2.0, 95% CI 1.1 to 3.4) with a
further step-up in risk for a high likelihood of exposure (HR 3.4,
95% CI 1.8 to 6.6, table 3). Furthermore, when divided into
separate exposure categories, a similar step-up in exposure risk
was manifest for mineral dust (HR 2.3, 95% CI 1.1 to 4.8 and
HR 2.9, 95% CI 1.1 to 7.2 for low and high likelihood,
respectively). When we excluded subjects with asthma from the
random sample, the ‘‘non-asthmatic random sample’’, the
results were quite similar, except for a higher step-up in risk
for high likelihood of exposure to mineral dust (table 3).
Sex was not associated with increased risk for respiratory
work disability in any of the multivariate models. The HR for
female sex vs male sex was 1.2 (95% CI 0.7 to 2.0) (data not shown
in table 3). In order to assess any potential sex-occupational
Table 1 Characteristics of the random sample and asthma cohort in a longitudinal study of respiratory
disability
Variable
Random sample Asthma cohort
Respiratory work disability Respiratory work disability
No Yes No Yes
No 6588 71 741 38
Mean (SD) age (years) 43.5 (6.8) 41.6 (6.6) 42.9 (6.9) 43.0 (6.9)
Mean (SD) BMI (kg/m2) 25.5 (4.4) 25.9 (3.8) 25.6 (5.0) 25.3 (3.4)
Females, n (%) 3327 (50.5) 34 (47.9) 385 (52.0) 26 (68.4)
Smoking at baseline, n (%)
Never smokers 2835 (43.0) 34 (47.9) 374 (50.5) 19 (51.3)
Former smokers 1441 (21.9) 14 (19.7) 151 (20.4) 11 (29.0)
Current smokers 2312 (35.1) 23 (32.4) 216 (29.2) 8 (21.1)
Passive smoking, n (%) 1892 (28.7) 20 (28.2) 196 (26.5) 13 (34.2)
Atopy, n (%)* 1570 (28.3) 20 (37.7) 413 (65.9) 19 (61.3)
Mean (SD) FEV1 (% predicted){ 106.4 (13.3) 102.2 (14.9) 99.2 (15.5) 96.8 (16.6)
Mean (SD) symptom score at
baseline
0.48 (0.94) 1.24 (1.53) 2.16 (1.66) 2.55 (1.66)
Physician-diagnosed asthma, n (%) 382 (5.8) 12 (16.9) 741 (100) 38 (100)
Rhinitis, n (%) 1598 (24.3) 25 (35.2) 473 (63.8) 27 (71.1)
*n = 5603 (random sample), n = 658 (asthma cohort). {n = 6084 (random sample), n = 709 (asthma cohort).
BMI, body mass index; FEV1, forced expiratory volume in 1 s.
Table 2 Occupational exposure in the random sample and asthma cohort
Variable
Random sample Asthma cohort
Respiratory work disability Respiratory work disability
No Yes No Yes
No 6588 71 741 38
Any exposure
None 3635 (55.2) 24 (33.8) 412 (55.6) 18 (47.4)
Low 1997 (30.3) 27 (38.0) 236 (31.9) 12 (31.6)
High 956 (14.5) 20 (28.2) 93 (12.6) 8 (21.1)
Biological dust
None 4715 (71.6) 46 (64.8) 530 (71.5) 24 (63.2)
Low 1617 (24.5) 21 (29.6) 188 (25.4) 11 (29.0)
High 256 (3.9) 4 (5.6) 23 (3.1) 3 (7.9)
Exposure to mineral dust
None 5054 (76.7) 39 (54.9) 577 (77.9) 28 (73.7)
Low 1073 (16.3) 21 (29.6) 118 (15.9) 7 (18.4)
High 461 (7.0) 11 (15.5) 46 (6.2) 3 (7.9)
Exposure to gases and fumes
None 3938 (59.8) 29 (40.9) 440 (59.4) 18 (47.4)
Low 2077 (31.5) 29 (40.9) 234 (31.6) 15 (39.5)
High 573 (8.7) 13 (18.3) 67 (9.0) 5 (13.2)
Exposure to passive smoking at
workplace (at baseline), n (%)
1892 (28.7) 20 (28.2) 196 (26.5) 13 (34.2)
Occupational lung disease
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exposure interaction, however, we reanalysed the data stratified
by sex. In men, any high exposure to biological dust, mineral dust
or gases or fumes was a strong predictor of respiratory work
disability (HR 4.2, 95% CI 1.8 to 9.9). In women, the point
estimate of risk related to any high exposure to biological dust,
mineral dust or gases or fumes was lower and the 95% CI did not
exclude unity (HR 2.1, 95% CI 0.5 to 9.4).
Atopy was not associated with an increased risk for
respiratory disability (HR 1.5, 95% CI 0.8 to 2.6). Moreover,
stratifying by atopy yielded estimates of occupational exposure
risk among atopic subjects (HR 3.0, 95% CI 0.8 to 11.2) and
non-atopic subjects (HR 4.0, 95% CI 1.5 to 10.6) that did not
differ substantively from each other.
Asthma cohort
In the asthma cohort a high likelihood of occupational exposure
to any biological dust, mineral dust or gases or fumes was
associated with an increased risk of respiratory work disability
(HR 3.5, 95% CI 1.4 to 9.0) that was not substantively different
from that estimated in the random sample (table 3). When the
separate exposure categories were analysed within the asthma
cohort, the pattern of risk contrasted with that in the random
sample: the highest point estimates were observed for biological
dust and gases and fumes, although the 95% CIs did not exclude
unity for any of these.
In contrast to the random sample, in the multivariate analysis
of the asthma cohort women were at increased risk for
respiratory work disability compared with men (HR 2.8, 95%
CI 1.3 to 5.9). Stratifying by sex, occupational exposure to
biological dust, mineral dust or gases or fumes in men imparted
a markedly increased risk (HR 12.8, 95% CI 2.8 to 59.0) which
was not the case in the women (HR 1.3, 95% CI 0.2 to 10.5).
Atopy was not associated with an increased risk for
respiratory disability (HR 0.8, 95% CI 0.4 to 1.7), and stratifying
for atopy yielded similar estimates of occupational exposure risk
in subjects with atopic asthma (HR 3.5, 95% CI 0.9 to 13.3) and
in those with non-atopic asthma (HR 3.9, 95% CI 0.5 to 27.6).
There was no significant effect of the symptom score (HR 1.2
per one point increase, 95% CI 1.0 to 1.4). Among those
reporting one symptom (n = 135) compared with those report-
ing no symptoms (n = 169), the risk of respiratory disability was
not clearly affected (HR 1.9, 95% CI 0.6 to 6.1) for one
symptom. Among those reporting five symptoms (n = 90)
compared to none, the risk was doubled (HR 2.4 (95% CI 0.7
to 8.0)), although the confidence interval included unity.
Additional analyses
Neither active smoking (either current, former or pack-years)
nor second hand smoke exposure appeared to carry a risk for
respiratory work disability. In all of the multivariate models, the
HRs for the different smoking variables ranged from 0.7 to 1.3
with confidence intervals always including unity in all cases. As
an additional sensitivity analysis we further retested the full
model replacing the symptom score with baseline FEV1%. The
results were similar, yielding increased HRs for high likelihood
for any occupational exposures.
DISCUSSION
The key message of this analysis is that workplace exposure to
dusts, gas or fumes is strongly associated with the subsequent
risk of respiratory work disability, a common adverse event.
Moreover, the present study is the first prospective general
population study showing that workplace exposures play a
substantial role in the occurrence of such disability, even taking
into account other demographic and clinical factors.
We defined disability as a job change resulting from
respiratory difficulties at work rather than a more extreme
criterion such as complete work cessation. Nonetheless, such
Table 3 Hazard ratio (HR) and 95% confidence intervals (95% CI) for respiratory work disability (ie, leaving
job because of affected breathing in a prospective international population-based study, the European
Community Respiratory Health Survey)
Occupational exposure
during follow-up
Random sample Asthma cohort
All Non-asthmatics
HR (95% CI)HR (95% CI) HR (95% CI)
Model 1{
Any exposure
None 1.0 1.0 1.0
Low 2.0 (1.1 to 3.4) 1.9 (1.0 to 3.5) 1.2 (0.6 to 2.5)
High 3.4 (1.8 to 6.6) 3.6 (1.8 to 7.2) 3.5 (1.4 to 9.0)
Model 2{*
Biological dust
None 1.0 1.0 1.0
Low 0.7 (0.4 to 1.4) 0.7 (0.4 to 1.4) 0.6 (0.2 to 1.7)
High 0.9 (0.3 to 2.6) 1.0 (0.3 to 2.9) 3.2 (0.7 to 13.7)
Mineral dust
None 1.0 1.0 1.0
Low 2.3 (1.1 to 4.8) 3.6 (1.5 to 8.7) 0.9 (0.3 to 2.5)
High 2.9 (1.1 to 7.2) 4.0 (1.4 to 11.5) 1.0 (0.2 to 5.1)
Gases and fumes
None 1.0 1.0 1.0
Low 1.4 (0.6 to 3.0) 0.9 (0.4 to 2.3) 2.2 (0.8 to 5.9)
High 1.7 (0.6 to 4.5) 1.1 (0.4 to 3.4) 3.5 (0.8 to 15.6)
Two populations were examined, a random sample and a sample of subjects with physician-diagnosed asthma at baseline, the
asthma cohort.
*For specific occupational exposures also mutual adjustments for exposures during follow-up.
{Adjusted for sex, age, smoking status at baseline, geographical area and exposure to passive smoking at baseline. The model for
the asthma cohort also included symptom score at baseline.
Occupational lung disease
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exposure-related job change is a reasonable marker of disability
more broadly defined, subsuming lost work time, decreased
productivity and complete job loss.
The results from this prospective study build on the findings
of previous cross-sectional analyses. In our earlier analysis of the
baseline population (ECRHS I), job change attributed to
breathing difficulties was common, affecting approximately
4% of the random population and 12% of those with asthma.7
In that cross-sectional study, asthma-related occupational
exposures carried a threefold risk of job change attributed to
breathing problems.7 Other cross-sectional studies have also
shown that various workplace exposures are of importance for
respiratory work disability across income levels,2–6 16–18 and
particularly in lower income working groups.6 19 20 Limited
longitudinal data also support the role of occupation in
asthma-related work disability.21 22
This analysis has important potential limitations that should
be acknowledged. Occupational exposure misclassification
could have occurred but is unlikely to explain the positive
associations we observed. Had we relied on self-reported
exposure, this could have led to systematic misclassification
error (eg, reporting bias); JEM assignment misclassification is
more likely to be random and, to the extent operative, biasing
toward the null. Another source of misclassification could arise
in relation to diagnostic labelling because, in the asthma cohort,
some misclassification between asthma and chronic obstructive
pulmonary disease may be present. Given the relatively young
age distribution of the study group, however, such misclassifi-
cation is unlikely to be a major factor.23 24 Having an occupation
with a high physical demand is probably associated with an
increased risk for respiratory disability.2 In this study we did not
analyse the impact of physical exertion, which may be a
confounder as dust-exposed blue collar occupations often are
physically demanding.
Confounding bias may also affect this analysis. Our random
population sample is not free of subjects with asthma. Because
persons with illness are not excluded, this random sample
should provide meaningful estimates of respiratory disability
rates for the populations from which they were drawn. By the
same token, the subset of those with disease theoretically could
mediate some of the occupational exposure risk, leading to
potential confounding. We addressed this by running a separate
analysis for the population with the asthmatic subjects
excluded (ie, the non-asthmatic random sample). The results
were quite similar to those for the total random sample, except
for mineral dust which was associated with a higher risk of
respiratory work disability.
The current baseline population started with a working
population, hence it may be possible that the asthmatic subjects
were already self-selected into jobs that did not exacerbate their
asthma and they may, to some extent, represent a healthy
survivor population which would lead to an underestimation of
the current exposure risks.
In addition to respiratory status, we also took into account
other key confounders including the geographical region from
which the subjects were drawn, active and second hand
smoking (at work), age, atopic status and sex. Among these
potential confounders, sex-related effects were the most salient.
Women were at greater risk of disability, but only in the asthma
cohort. In stratified analyses, in contrast, men in both the
random sample and the asthma cohort were at substantively
higher risk of occupationally-related respiratory work disability.
These seemingly contradictory observations can be explained by
an effect in which occupational exposure intensity for any given
likelihood by JEM assignment is greater in men than women; in
those with asthma, female sex is indeed a risk factor for
respiratory disability, but this does not appear to be mediated
by occupational exposure factors. Of note, previous cross-
sectional analyses failed to show this sex-related pattern.7
The respiratory disability outcome central to this analysis
was based on self-reporting. We did not validate these reports
through external sources such as employment records or various
social security measures (which would, in any event, have
varied widely among the international centres). Nonetheless,
disability in epidemiological studies is commonly measured by
survey definitions dependent on self-reporting and thus our
measure is comparable with others widely reported in the
literature on this subject. One other limitation is that the
approach we used does not capture changes of job activities or
duties within the same job.
Finally, because this was a random multinational study, our
results should have an external validity for other similar
populations. Nonetheless, our findings may not extend to
certain other populations such as those in emerging economies
with different patterns of occupational exposure or profound
disincentives to job change even in the face of work-related
respiratory symptoms.
In summary, we found that over a period of 8 years, 1% of
the population attributed job changes to respiratory problems
while, among those with asthma, the cumulative incidence of
such change was even higher (approximately 1 in 20). These
findings suggest that, during a working career, 5% of all workers
will experience such disability and, among those with asthma,
25% might face this challenge. This disability may be
preventable in part if working conditions bringing exposure to
dusts, gas and fumes were ameliorated.
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